Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


USP forum goes gratis

This article was originally published in The Tan Sheet

Executive Summary

The Pharmacopeial Forum becomes a free online resource starting in January, the U.S. Pharmacopeia says Sept. 8, allowing "greater participation in the standards-setting process for drugs, excipients and dietary supplements." PF is the nonprofit group's journal for public comment, giving manufacturers, regulators and other stakeholders a chance to provide feedback on proposed standards before they become official in USP's National Formulary. The May-June issue of PF sought comments on standards for bacopa monnieri, garcinia gummi-gutta and other Indian botanicals used in supplements and traditional medicines (1"The Tan Sheet" May 10, 2010, In Brief)

You may also be interested in...

USP standardizes Indian botanicals

The U.S. and Indian pharmacopeias jointly propose standards for the identity, strength, quality and purity of four botanical articles in multiple forms used in U.S. dietary supplements and Indian traditional medicines. Monographs for the botanicals bacopa monnieri, garcinia gummi-gutta, garcinia indica and plectranthus barbatus are in the May-June issue of Pharmacopeial Forum, USP said May 5. The Rockville, Md.-based organization seeks comments on the standards before they are finalized. USP will publish official monograph standards for the botanicals ashwagandha root, andrograpahis aerial parts and boswellia serrata in February 2011, USP said

EU Firsts Beckon For Olumiant In Dermatitis & Orfadin For AKU

The European Medicine Agency has recommended extending the therapeutic indication of a raft of drugs that are already authorized in the EU.

Roche Bulks Up In NLRP3 With €380m Inflazome Buy

Having acquired Jecure Therapeutics and its preclinical portfolio of NLRP3 inhibitors just under two years ago, the Swiss giant has swooped in to buy Dublin-based Inflazome and expand its presence in a hot field of inflammatory research.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts